Ten trained patients with typical angina pectoris took part in a double-blind cross-over study to assess the effects on exercise tolerance of 50 and I00 mg alprenolol and placebo, on three successive days. On the fourth day, a known dose of 200 mg alprenolol was given.
alprenolol compared to placebo on effort capacity in trained subjects with angina pectoris by means of ergometry. Placebo, 50, and ioo mg tablets of alprenolol were given in a random order in a double-blind cross-over manner on three successive days, and on the fourth day a known dose of 200 mg alprenolol was given to each patient. The reason not to include the 200 mg dose in the double-blind allocation was that no previous experiences of a single first oral dose of that size in angina patients were at hand.
Despite the fact that many studies on betablocking drugs have been reported previously, we have been unable to find an account of a similar dose-response study. Most of the patients who took part in the previous intravenous study also agreed to participate in the present study during their hospital stay, whereby a comparison between oral and intravenous doses was also made.
Subjects and methods
Ten male patients between the ages of 44 and 69 (mean age 60) years were studied. Body weights ranged from 70 to 93 (mean 8i) kg. All had typical exertional angina pectoris while walking at normal speed on the level, and in some cases at rest or while getting dressed, for at least one year. None had established diastolic hypertension, valvular heart disease, heart failure, or cardiac infarction within three months. Three patients had a verified history of previous myocardial infarction. Anti- anginal drugs other than sublingual nitroglycerin were not used two weeks before the study. The patients were studied as inpatients in hospital and tested at the same time of the day. They abstained from tobacco before testing and were instructed not to take nitroglycerin later than 2 hours before the exercise tests.
Between 3 and 9 exercise tests were performed on a mechanically braked bicycle ergometer (Monark, Varberg, Sweden) according to a standard procedure, with stepwise increasing work loads until anginal pain according to Sj6strand (I967) . In this way, the patients became familiarized with the experimental procedure. On the basis of these control tests, a work load which could be expected not to produce unendurable anginal pain before 6 to I2 minutes was chosen for each individual patient. Two patients (Cases 3 and 7) were found to have great difficulties if the starting work load was too large. In these patients, a rather low starting load was chosen and increased in a stepwise manner at 6-minute intervals (cf. Table 3 gives the number of patients having less, equal, and more ST depression at various times during the exercise on the different dose levels. With increasing dose and increasing amount of work performed, the number of patients having less ST depression than on placebo increases, indicating a decrease of cardiac ischaemia in a larger number of patients. The electrocardiographic normalization time is also shortened after alprenolol, the mean reduction being 27 per cent after the Ioo mg dose and 48 per cent after the 2oo mg dose.
Alprenolol produced a dose-dependent reduction of heart rate and systolic blood pressure after 4 minutes' exercise. At the onset of anginal pain and at the end of exercise, 2oo mg alprenolol produced a significantly larger reduction of heart rate (P < o.oI) and systolic blood pressure (P < 0.02) than did the Ioo mg dose. At rest (sitting on the bicycle) there is a small but statistically significant reduction of heart rate (5-Io beats/minute) on all dose levels, whereas systolic blood pressure at rest is insignificantly influenced.
All mean values are given in Table 2 .
Individual results Eight patients improved (see Table i ). All these patients had a fall in heart rate and systolic blood pressure at the end of exercise. Two patients could not increase their exercise tolerance on any dose of alprenolol compared to placebo. One of these patients (Case Io) had on placebo a resting heart rate of 48 beats a minute and the comparatively low heart rate of 95 beats a minute In 2 patients (Cases I and 2), the 50 mg dose was as effective as the ioo mg dose.
These 2 patients showed a much larger reduction of heart rate on the 50 mg dose than the rest of the alprenolol responders. At 4 minutes' exercise, the heart rate of Case i decreased from 125 to io8 beats/minute and that of Case 2 decreased from I25 tO ioo beats/ minute on the 50 mg dose, whereas the corresponding mean change for the remaining 6 alprenolol responders on the 50 mg dose was from I20 ± I I to I1 5 ± 9 beats/minute (N.S.).
Four patients showed less improvement of exercise tolerance after the 200 mg dose than after the i00 mg dose. Three of these patients (Cases 2,3, and 4)had a considerably greater reduction in systolic blood pressure during exercise after 200 mg alprenolol than the other responders. The difference from the I00 mg value at the end of exercise for these 3 patients was 30, 35, and 40 mmHg respectively, whereas the corresponding mean difference for the remaining 5 alprenolol responders was 7 ± 4-3 mmHg. Comparison with effects of intravenous alprenolol For the 8 patients who also took part in the previous intravenous study, mean values for heart rate and systolic blood pressure at 4 minutes' work, time until pain appeared, electrocardiographic normalization time, and total work have been summarized in Table 4 for the intravenous study (active drug and placebo) and the present study (ioo mg dose and placebo). The placebo values in the two studies for the variables mentioned do not differ significantly from one another, and the changes induced by intravenous alprenolol caused a statistically significant delay of the appearance of anginal pain during standardized exercise and an increase of the total work performed. Alprenolol did not influence the duration of pain after end of exercise but reduced significantly the duration of ST depression.
The present results with I00 mg alprenolol are in general agreement with those reported byAdolfsson etal. (I97i). These authors found on the average a greater increase of exercise tolerance after alprenolol than in the present study. This difference might be related to the fact that the patients of Adolfsson et al. could endure significantly less exercise after placebo than our patients.
After 50 mg alprenolol, some patients improved in the present study, but statistically the mean exercise tolerance and electrocardiographic changes were not significantly different from placebo.
The exercise studies were carried out ij hours after administration of the tablets, at which time the beta-blocking action of orally given alprenolol reaches its peak (Ablad et al., I967b) . Studies in healthy students of the effect of orally given alprenolol on the tachycardia response to repeated exercise indicate that the beta-blocking action of I00 mg alprenolol persists for more than 7 hours, while that of 50 mg is weaker and is of shorter duration (Ablad et al., I97I) .
On the basis of these human pharmacological data and the present clinical investigation, alprenolol in a dose of ioo mg q.i.d. should be of therapeutic value in the long-term treatment of angina pectoris, while a dose of 50 mg q.i.d. should have little effect in most cases. This hypothesis is supported by the results from some studies where the clinical effects of alprenolol, given over 2 to 4 weeks, were compared with placebo with double-blind crossover technique. As 8 of the I0 patients in the present series also took part in a previous intravenous alprenolol study, it is of interest to compare the results in these 8 patients in the two trials.
The effect of ioo mg alprenolol orally was not significantly different from o0i mg/kg i.v. (mean total dose 8-2 mg) with regard to increase of total work and reduction of exercise heart rate. This is approximately in accordance with previous studies on dose-effect relations between orally and intravenously given alprenolol as regards antagonism to isoprenaline-induced tachycardia in healthy volunteers (Johnsson, Norrby, and Solvell, 1967) .
The relevance of the data obtained after 200 mg alprenolol in the present study should be judged with caution as this dose was deliberately given on the last day of the trial in each patient. Certain facts, however, justify the inclusion of the effects of the 200 ,mg dose in an overall comparison between the various doses. The patients had carried out 6 to 9 exercise tests shortly before the present study. In the 8 patients who took part both in the present trial and the previous study with intravenous alprenolol, the mean total work performed on placebo in the two investigations was practically the same.
Furthermore, the sums of total work performed in each of the three consecutive exercise days with randomized drug administration in the present trial scarcely differed.
Thus, factors such as physical training or unfamiliarity with the test procedure could not have influenced the variation between tests much.
The mean results obtained after 2oo mg alprenolol indicate that this dose produced about the same reduction of ST depression as Ioo mg alprenolol, but exercise tolerance improved, if anything, less than on the Ioo mg dose.
It thus appears that alprenolol had on an average its most pronounced positive effect on exercise tolerance in a dose of Ioo mg in this type of study. However, the data indicate that there may be individual variations as regards the optimal dose. Of the I0 patients, 2 showed an optimum improvement of exercise tolerance after 50 mg, and 3 others after 2oo mg alprenolol. So far no long-term studies have been published about the anti-anginal effect of alprenolol in doses above Ioo mg q.i.d.
The therapeutic effect of alprenolol in angina pectoris is probably due to the betablocking activity ofthe drug (Bjorntorp, I968) . Beta-blockers, such as alprenolol and propranolol, reduce the myocardial oxygen demand in situations with increased adrenergic activity in the dog heart (Ek and Ablad, I970).
This effect is probably mainly a consequence of inhibition of the adrenergic control of cardiac rate and contractility (Epstein and Braunwald, I966) . Such inhibition leads to decreased heart rate and arterial blood pressure, which should result in reduced cardiac work, in turn leading to diminished myocardial oxygen consumption. Adrenergic blockade of cardiac chronotropic and inotropic stimuli further influences myocardial oxygen demand in several other ways, both reducing it, for example through a decrease of the speed of ventricular contraction, and increasing it, for example through an enlargement of cardiac size (Epstein and Braunwald, I966) .
While the therapeutic effect of betablockers in angina pectoris has hitherto largely been discussed as a matter of interference with the oxygen demand of the myocardium, secondarily to its function as a pump, it should be kept in mind that the agents may also influence the delivery of oxygen to the myocardium. A decrease of coronary blood flow has been observed after propranolol both in animals (McKenna et al., I966; Parratt, I967; Stein et al., I968) and in man (Wolfson and Gorlin, I969) . It is likely that this increase of coronary vascular resistance is mainly a consequence of the reduced myocardial oxygen demand (Lucchesi and Whitsitt, I969), but in part it may be an expression of alpha-receptor mediated adrenergic vasoconstrictor activity on the coronary resistance vessels (Feigl, I967; Parratt, I967) . In some studies the arteriovenous myocardial oxygen difference has been found to be increased after propranolol (McKenna et al., I966; Wolfson and Gorlin, I969), and it has been suggested that propranolol reduces the myocardial oxygen supply more than it decreases the myocardial requirement for oxygen in the heart as a whole (Parratt and Grayson, I966) . Some recently reported studies with propranolol on dogs with regional myocardial ischaemia have yielded results (Craven and Pitt, I968; Becker et al., i969a; Becker, Fortuin, and Pitt, I969b) that may be pertinent to the therapeutic effect of betablockade in angina pectoris. These studies showed that propranolol reduced blood flow to normal myocardium but not to areas of ischaemia. This selective maintenance of flow after beta-blockade may imply an improvement in the relation between oxygen delivery and demand in the ischaemic regions, provided the myocardial oxygen requirements are reduced by beta-blockade in the ischaemic areas as in the rest of the myocardium. The mechanism behind the described redistribution of coronary blood flow after propranolol has not yet been elucidated.
Animal studies indicate that beta-blockade may also influence the oxygen economy of the myocardium through a direct interference with its cellular metabolism. Propranolol has been found to reduce myocardial uptake of free fatty acids with a consequent relative rise in the myocardial carbohydrate utilization (Marchetti, Merlo, and Noseda, I968; Masters and Glaviano, I969 (Challoner and Steinberg, I966) .
While the relative importance of the above discussed factors is so far incompletely elucidated, it seems evident that the integrated response to beta-blockade in most angina patients is an improvement of the relation between myocardial oxygen demand and delivery. It would otherwise be difficult to explain the well-documented therapeutic effect of the drugs, whether expressed as increase of exercise tolerance, reduction of ST depression during exercise, or decrease of attack rate under long-term administration. The beta-blockers should be expected to be particularly effective in angina patients where the attack-producing imbalance of the oxygen economy of the myocardium is mainly due to activation of the cardiac beta-receptors. Patients with hyperkinetic circulation appear to be characterized by such a reaction pattern (Frohlich, Dustan, and Page, I966) and the beta-blockers have been found to be especially effective in angina patients with a hyperkinetic response to standing (Furberg and Jacobsson, I967) and exercise (Cullhed, 1971) .
The heart rate and systolic blood pressure are the most simply measured parameters reflecting cardiac beta-receptor blockade. From the foregoing discussion one would not expect to find any simple correlation between the effects of alprenolol on exercise tolerance on the one hand, and on exercise heart rate and systolic blood pressure on the other. That some correlation exists, however, is suggested by the study of Kimura, Yoshida, and Ushiyama (I967). These authors investigated propranolol and pronethalol in angina pectoris, by means of exercise tolerance tests, and concluded that when one of the drugs was effective, the product of systolic pressure and heart rate during angina decreased compared to the control value, whereas when this product did not decrease, the patient had no improvement of the angina.
The present results show on the average no direct correlation between the anti-anginal effect of alprenolol and its reduction of the heart rate and blood pressure. Vhile the doseresponsive curve as regards the effect of alprenolol on exercise tolerance seemed to reach a peak at a dose of ioo mg on average, the drug-induced reduction of exercise heart rate and systolic blood pressure followed a different pattern, the 200 mg dose being most effective. An examination of the individual cases revealed, however, some interesting relations between the effects on exercise tolerance and on heart rate -blood pressure. Of the 2 patients whose exercise tolerance worsened or was unchanged after alprenolol, one showed practically no decrease of exercise heart rate, while the other showed no decrease of exercise systolic blood pressure after any dose of alprenolol. The remaining 8 patients whose exercise tolerance improved on alprenolol all responded to the drug with a distinct reduction of the heart rate and blood pressure. The 2 patients showing most obvious improvement of exercise tolerance after 50 mg alprenolol also had the most pronounced reduction of exercise heart rate of all patients on this dose.
Three patients had a much more pronounced reduction of systolic blood pressure after 200 mg alprenolol than after Ioo mg, but their exercise tolerance was lower after the higher dose. This finding represents the most obvious deviation from a direct correlation between the anti-anginal effect and the blood pressure reduction. The mechanism behind this finding is not clear. One possibility is that the oxygen delivery to the myocardium was critically lowered because of the decreased arterial pressure. Another possible factor is that the hypotensive reaction created a deficient blood flow to the exercising muscles, so that the patients had to stop exercise, in part, because of tiredness in the legs. Though this was not spontaneously reported by the patients, the latter hypothesis is supported by the fact that the decreased exercise tolerance was not accompanied by more pronounced ST depression.
Like previous acute and more prolonged studies of the effect of alprenolol in angina pectoris patients, the present investigation indicates that the drug, when given in proper doses, is an effective and safe therapeutic agent in the majority of patients. It appears important to analyse whether acute exercise tests, as made in the present study, could be of value in predicting therapeutic response and optimal dosage during long-term treatment with beta-blockade in the individual angina patient. Positive findings in this regard imply a more rational basis for therapy than the patients' subjective impressions, which are now the most widely used therapeutic criteria in the routine assessment of these agents. 
